Technology Overview
Multicellular tumour spheroids (MCTS) are widely accepted as physiologically relevant 3D in vitro tumour models, offering improved predictive value over conventional 2D cultures for drug screening and efficacy testing. CSIR has developed a novel thermoresponsive copolymer additive (P149-mPEG350) that enables rapid and reproducible formation of compact tumour spheroids using the widely adopted hanging-drop method.
The additive enhances cell aggregation, droplet stability, and spheroid compaction within 24–48 hours, supporting robust spheroid generation across diverse cancer cell types.
Problem Addressed
There is a strong unmet need for simple, reproducible additives that improve speed and consistency of spheroid formation. Current spheroid generation methods face:
- Longer formation times (3–5 days)
- Limited reproducibility across multiple tumour cell types
- Workflow variability in hanging-drop cultures
- Dependence on expensive ECM substrates (e.g., Matrigel)
- Challenges in scalability for screening environments
Innovation & Novelty
The invention introduces a defined thermoresponsive copolymer composed of repeating units of:
- N-isopropylacrylamide (NIPAm)
- Styrene
- Vinyl pyridine
- Polyethylene glycol (PEG)
Unlike existing PEG/polyNIPAm-based systems, prior art does not disclose the specific polymer composition P149-mPEG350 or its demonstrated ability to generate robust spheroids across multiple distinct cell lines using hanging-drop culture. Conventional polyNIPAm alone fails to produce stable spheroids in several tumour models, whereas P149-mPEG350 enables consistent, compact spheroid formation across diverse cell types.
Value Proposition
A patent-protected, biocompatible polymer additive enabling formation of compact, pharma-grade tumour spheroids within 24–48 hours, with enhanced droplet stability and high cell viability — supporting faster, more reproducible oncology drug discovery and preclinical screening workflows.
This innovation aligns with industry priorities in:
- Predictive oncology screening platforms
- Scalable 3D tumour biology models
- Reproducible hanging-drop spheroid workflows
- Reduced dependence on animal models (3Rs-driven R&D)
Applications
- Oncology Drug Discovery & Screening — Rapid tumour spheroid generation for anticancer compound screening in physiologically relevant 3D models.
- Preclinical Toxicity & Efficacy Testing — Improved prediction of therapeutic response compared to conventional 2D assays.
- 3D Tumour Biology Research — Enables studies of hypoxia gradients, drug penetration kinetics, and resistance mechanisms.
- Spheroid Culture Reagent & Kit Development — Strong potential for integration into commercial spheroid-generation kits and consumables.
- CRO-Based Screening Platforms — Applicable to CRO workflows requiring reproducible spheroid-based oncology screening.
- Personalized Oncology Potential — Technology may be extendable to patient biopsy-derived spheroids, supporting individualized therapy response evaluation.
Market Opportunity
ECM-based substrates such as Matrigel remain widely used as the current gold standard, particularly in organoid studies. P149-mPEG350 is positioned as a synthetic, reproducible additive that can complement or provide an alternative to existing scaffold-dependent approaches, especially in hanging-drop spheroid workflows.
The global spheroid culture market is rapidly expanding:
Competitive Advantages
| Feature | Existing Approaches | P149-mPEG350 Additive |
|---|---|---|
| Formation time | 3–5 days | 24–48 hours |
| Cell line versatility | Often limited | Validated across 5+ cell lines |
| Workflow complexity | ECM-heavy or multi-step | Simple drop-in additive |
| Hanging-drop consistency | Variable droplet stability | Enhanced droplet support |
| Cost dependency | High reliance on Matrigel | Synthetic polymer additive |
| Spheroid morphology | Variable | Compact and reproducible |
Current Status of Technology
- Laboratory validated across multiple cell lines — MCF-7 (Breast cancer), Liver cancer, Cervical cancer, Lung carcinoma, and Human embryonic kidney
- Demonstrated spheroid viability and compactness
- Initial drug screening proof-of-concept available
- Ready for industry evaluation, scale-up, and co-development
Technology Readiness Level (TRL): 4 — Technology Validated at Laboratory
IP Status
Licensing & Collaboration Opportunities
CSIR invites partnerships for:
- Licensing to 3D cell culture reagent and kit manufacturers
- Co-development of ready-to-use spheroid generation additives
- Pharma oncology screening validation partnerships
- CRO adoption for high-throughput spheroid workflows
- Extension toward patient-derived tumour spheroid platforms